eligibility_summary
Adults (≥18) with confirmed ES‑SCLC, archival tissue, ECOG 0–1, eligible for 1L platinum+etoposide+anti‑PD‑L1 (A: carbo+etoposide+atezo, B: etoposide+carbo/cis+atezo/durva). No prior systemic ES‑SCLC therapy, prior limited‑stage therapy ended ≥6 mo earlier. Exclude prior trial drug, recent systemic Tx/RT/major surgery, leptomeningeal disease, prior DLL3 TCEs, unresolved >G1 toxicity, or other malignancy ≤5 yrs (except basal cell/cervical in situ). More criteria apply.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06077500 (DAREON-8) tests BI 764532 (obrixtamig) added to first‑line standard therapy for extensive-stage SCLC. Interventions: • BI 764532: a DLL3×CD3 T‑cell engager (bispecific, antibody‑like) that binds DLL3 on SCLC cells and CD3 on T cells to redirect and activate cytotoxic T‑cell killing, targets DLL3 (tumor) and CD3/T‑cell activation pathways. • Atezolizumab or durvalumab: anti‑PD‑L1 monoclonal antibodies (checkpoint inhibitors) that block PD‑L1 to restore anti‑tumor T‑cell activity, target PD‑1/PD‑L1 axis on tumor/immune cells. • Carboplatin or cisplatin: platinum chemotherapies that form DNA crosslinks, target DNA damage/repair pathways in rapidly dividing tumor cells. • Etoposide: topoisomerase II inhibitor causing DNA double‑strand breaks, targets DNA replication/repair pathways. The trial escalates BI 764532 doses with platinum‑etoposide plus PD‑L1 blockade.